Tibotec

From Wikipedia, the free encyclopedia

Tibotec is a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV (AIDS), and Hepatitis C. The company develops antiretroviral drugs for the treatment of AIDS.

Contents

[edit] History

In 1994, Rudi Pauwels (Rega Institute for Medical Research) founds Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels (Janssen Pharmaceutica) joins Tibotec. The company was acquired by Johnson & Johnson in April 2002. The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium)[1].

[edit] Drugs

  • TMC114 (darunavir), a protease inhibitor (PI), (recently approved by the FDA)
  • TMC125, (etravirine) a non-nucleoside reverse transcriptase inhibitor (NNRTI),
  • TMC278, (rilpivirine) a NNRTI.

Tibotec licensed TMC120, a NNRTI, to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.

[edit] References

  1. ^ Pauwels R, Andries K, Desmyter J, Schols D, Kukla MJ, Breslin HJ, Raeymaeckers A, Van Gelder J, Woestenborghs R, Heykants J, et al., Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives, Nature. 1990 Feb 1;343(6257):470-4

[edit] See also

[edit] External links

In other languages